npj Breast Cancer

Papers
(The TQCC of npj Breast Cancer is 15. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Biological correlates associated with high-risk breast cancer patients identified using a computational method309
Sequence of therapy impact on older women with comorbidities and triple-negative or HER2-positive breast cancer171
Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab169
Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancer155
Circulating tumor cells in breast cancer: clinical validity and utility143
Reversion of breast epithelial polarity alterations caused by obesity121
Prediction models for hormone receptor status in female breast cancer do not extend to males: further evidence of sex-based disparity in breast cancer101
The deubiquitinating enzyme USP4 regulates BRCA1 stability and function92
Breast cancer survivors’ opinion on personalizing endocrine therapy and developing informative tools88
Discerning the impact of ctDNA detection on patient decision-making in early-stage breast cancer86
The clinical and molecular significance associated with STING signaling in breast cancer74
Current gene panels account for nearly all homologous recombination repair-associated multiple-case breast cancer families69
Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer66
Decreased enrollment in breast cancer trials by histologic subtype: does invasive lobular carcinoma resist RECIST?64
IHC-based Ki67 as response biomarker to tamoxifen in breast cancer window trials enrolling premenopausal women63
Heparanase: a potential marker of worse prognosis in estrogen receptor-positive breast cancer62
Molecular signatures of in situ to invasive progression for basal-like breast cancers: An integrated mouse model and human DCIS study61
UACA locus is associated with breast cancer chemoresistance and survival58
Tocilizumab overcomes chemotherapy resistance in mesenchymal stem-like breast cancer by negating autocrine IL-1A induction of IL-654
C/EBPβ isoform-specific regulation of migration and invasion in triple-negative breast cancer cells54
Subclonal heterogeneity and evolution in breast cancer50
Publisher Correction: Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models49
Clinical relevance of pathogenic germline variants in mismatch repair genes in Chinese breast cancer patients49
HBXIP induces anoikis resistance by forming a reciprocal feedback loop with Nrf2 to maintain redox homeostasis and stabilize Prdx1 in breast cancer49
Prognostic significance of RNA-based TP53 pathway function among estrogen receptor positive and negative breast cancer cases48
Changes in intestinal microbiota in postmenopausal oestrogen receptor-positive breast cancer patients treated with (neo)adjuvant chemotherapy46
Increased trunk fat is associated with altered gene expression in breast tissue of normal weight women44
Author Correction: FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer43
Characterisation of PALB2 tumours through whole-exome and whole-transcriptomic analyses42
GATA3 and markers of epithelial-mesenchymal transition predict long-term benefit from tamoxifen in ER-positive breast cancer42
Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer41
Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial39
Evaluation of multigene assays as predictors for response to neoadjuvant chemotherapy in early-stage breast cancer patients38
Extended adjuvant endocrine therapy in a longitudinal cohort of young breast cancer survivors38
ERα/PR crosstalk is altered in the context of the ERα Y537S mutation and contributes to endocrine therapy-resistant tumor proliferation37
High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer: the randomized phase III NeoTN trial37
CDK4/6i-treated HR+/HER2- breast cancer tumors show higher ESR1 mutation prevalence and more altered genomic landscape36
Molecular differences between younger versus older ER-positive and HER2-negative breast cancers35
International survey on invasive lobular breast cancer identifies priority research questions35
Author Correction: Characterization and spatial distribution of infiltrating lymphocytes in medullary, and lymphocyte-predominant triple negative breast cancers35
Spatial interplay of tissue hypoxia and T-cell regulation in ductal carcinoma in situ32
A biomarker of aging, p16, predicts peripheral neuropathy in women receiving adjuvant taxanes for breast cancer31
High B7-H3 expression with low PD-L1 expression identifies armored-cold tumors in triple-negative breast cancer31
Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade30
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer30
Utilizing cell-free DNA to predict risk of developing brain metastases in patients with metastatic breast cancer30
The impact of lymphedema on health-related quality of life up to 10 years after breast cancer treatment30
PI3K/AKT signaling activates HIF1α to modulate the biological effects of invasive breast cancer with microcalcification29
Multi-center study on predicting breast cancer lymph node status from core needle biopsy specimens using multi-modal and multi-instance deep learning29
Estrogen receptor-positive breast cancer and adverse outcome in BRCA2 mutation carriers and young non-carrier patients29
Hyperleptinemia in obese state renders luminal breast cancers refractory to tamoxifen by coordinating a crosstalk between Med1, miR205 and ErbB28
Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition28
MRI background parenchymal enhancement, breast density and breast cancer risk factors: A cross-sectional study in pre- and post-menopausal women27
Efficacy of platinum-based chemotherapy in metastatic breast cancer and HRD biomarkers: utility of exome sequencing27
PARP inhibition in breast cancer: progress made and future hopes27
Pak1 pathway hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer27
PAM50 subtyping and ROR score add long-term prognostic information in premenopausal breast cancer patients26
Immunotherapy for early triple negative breast cancer: research agenda for the next decade26
TGFβ-mediated MMP13 secretion drives myoepithelial cell dependent breast cancer progression26
HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment26
Therapeutic and immunomodulatory potential of pazopanib in malignant phyllodes tumor26
Clinical outcomes of de novo metastatic HER2-low breast cancer: a National Cancer Database Analysis25
Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis25
Automated quantification of levels of breast terminal duct lobular (TDLU) involution using deep learning25
Effects of socioeconomic status and race on survival and treatment in metastatic breast cancer24
Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors24
Integration of clinical features and deep learning on pathology for the prediction of breast cancer recurrence assays and risk of recurrence24
Dose dense versus 3 weekly AC during neoadjuvant chemoimmunotherapy for triple negative breast cancer24
Mortality after second malignancy in breast cancer survivors compared to a first primary cancer: a nationwide longitudinal cohort study24
Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy in metastatic breast cancer24
A perspective on the development and lack of interchangeability of the breast cancer intrinsic subtypes23
Baseline gut microbiome alpha diversity predicts chemotherapy-induced gastrointestinal symptoms in patients with breast cancer23
International research to address the challenges of metastatic breast cancer: the AURORA Program (BIG 14-01)23
Biological insights and novel biomarker discovery through deep learning approaches in breast cancer histopathology23
Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysis23
Racial discrimination among women seeking breast cancer care23
A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer23
Automated and rapid detection of cancer in suspicious axillary lymph nodes in patients with breast cancer22
The incidence of discordant clinical and genomic risk in patients with invasive lobular or ductal carcinoma of the breast: a National Cancer Database Study22
Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC22
Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies22
Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer22
Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study21
Primary endocrine resistance of ER+ breast cancer with ESR1 mutations interrogated by droplet digital PCR21
Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer21
Signaling of MK2 sustains robust AP1 activity for triple negative breast cancer tumorigenesis through direct phosphorylation of JAB120
Evaluation of the association of heterozygous germline variants in NTHL1 with breast cancer predisposition: an international multi-center study of 47,180 subjects20
Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trial20
Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study19
Overweight and prognosis in triple-negative breast cancer patients: a systematic review and meta-analysis19
Evaluation of multiple transcriptomic gene risk signatures in male breast cancer19
Development and pilot of an online, personalized risk assessment tool for a breast cancer precision medicine trial19
Comparative survival analysis of multiparametric tests—when molecular tests disagree—A TEAM Pathology study19
Associations with response to Poly(ADP-ribose) Polymerase (PARP) inhibitors in patients with metastatic breast cancer18
Adaptive stress response genes associated with breast cancer subtypes and survival outcomes reveal race-related differences18
Bone mineral density in women newly diagnosed with breast cancer: a prospective cohort study18
Management of the axilla in T1-2N1 breast cancer18
Integration of tumour sequencing and case–control data to assess pathogenicity of RAD51C missense variants in familial breast cancer18
Gene signatures in patients with early breast cancer and relapse despite pathologic complete response17
Survival outcomes after omission of surgery for ductal carcinoma in situ17
Plasma C-peptide mammographic features and risk of breast cancer17
Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer17
Overexpression of COL11A1 confers tamoxifen resistance in breast cancer17
Improving the odds together: a framework for breast cancer research scientists to include patient advocates in their research17
Acupuncture versus cognitive behavioral therapy for pain among cancer survivors with insomnia: an exploratory analysis of a randomized clinical trial17
Liquid biopsy for brain metastases and leptomeningeal disease in patients with breast cancer17
Enhanced immune response outperform aggressive cancer biology and is associated with better survival in triple-negative breast cancer17
Second breast cancer: recurrence score results, clinicopathologic characteristics, adjuvant treatments, and outcomes—exploratory analysis of the Clalit registry17
Assessment of MRI to estimate metastatic dissemination risk and prometastatic effects of chemotherapy17
Reporting on invasive lobular breast cancer in clinical trials: a systematic review17
Development and validation of a clinical breast cancer tool for accurate prediction of recurrence16
A polygenic score associated with fracture risk in breast cancer patients treated with aromatase inhibitors16
Reply to: PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer16
High GPER expression in triple-negative breast cancer is linked to pro-metastatic pathways and predicts poor patient outcomes15
SPP1+ macrophages in HR+ breast cancer are associated with tumor-infiltrating lymphocytes15
The search for CDK4/6 inhibitor biomarkers has been hampered by inappropriate proliferation assays15
Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer15
Sustained lymphocyte decreases after treatment for early breast cancer15
A panoptic segmentation dataset and deep-learning approach for explainable scoring of tumor-infiltrating lymphocytes15
Pyrotinib and trastuzumab plus palbociclib and fulvestrant in HR+/HER2+ breast cancer patients with brain metastasis15
Deep learning radiomics based prediction of axillary lymph node metastasis in breast cancer15
Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer15
Inhibition of CXorf56 promotes PARP inhibitor-induced cytotoxicity in triple-negative breast cancer15
Performance of an AI-powered visualization software platform for precision surgery in breast cancer patients15
Automated mitotic spindle hotspot counts are highly associated with clinical outcomes in systemically untreated early-stage triple-negative breast cancer15
0.088901042938232